INNOVATE BIOPHARMACEUTICALS, INC. Contracts & Agreements

Amendment No. 2 to the Forbearance Agreement (Filed With SEC on July 18, 2023)

Separation Agreement and Release between John Temperato and 9 Meters Biopharma, Inc., dated May 29, 2023 (Filed With SEC on May 30, 2023)

Amendment No. 1 to the Forbearance Agreement, dated May 18, 2023 (Filed With SEC on May 19, 2023)

Forbearance Agreement, dated April 26, 2023 (Filed With SEC on April 27, 2023)

Description of the Companys Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 28, 2023)

Form of Retention Bonus Agreement (Filed With SEC on March 28, 2023)

Form of Common Warrant (Filed With SEC on March 15, 2023)

Form of Pre-Funded Warrant (Filed With SEC on March 15, 2023)

Form of Placement Agent Warrant (Filed With SEC on March 15, 2023)

Form of Securities Purchase Agreement (Filed With SEC on March 15, 2023)

First Amendment to the Amended and Restated Senior Secured Convertible Note Due 2025 (Filed With SEC on January 13, 2023)

Form of Amended and Restated Senior Secured Convertible Note (Filed With SEC on November 8, 2022)

Lease Agreement by and between 9 Meters Biopharma, Inc. and Crabtree Terrace Holdings LLC, dated October 3, 2022 (Filed With SEC on October 6, 2022)

Exclusive License Agreement between 9 Meters Biopharma, Inc. and EBRIS srl (Filed With SEC on August 15, 2022)

Form of Securities Purchase Agreement (Filed With SEC on June 30, 2022)

Form of Senior Secured Convertible Note (Filed With SEC on June 30, 2022)

9 Meters Biopharma, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 22, 2022)

Form of 9 Meters Biopharma, Inc. Notice of Stock Option Grant and Award Agreement (Filed With SEC on June 22, 2022)

First Amendment dated July 12, 2021, to Employment Agreement dated April 30, 2020, between 9 Meters Biopharma, Inc. (formerly Innovate Biopharmaceuticals, Inc.) and John Temperato (Filed With SEC on March 23, 2022)

Employment Agreement between 9 Meters Biopharma, Inc. and Bethany Sensenig (Filed With SEC on January 18, 2022)

Separation and Consulting Agreement, dated January 14, 2022, between 9 Meters Biopharma, Inc. and Edward J. Sitar (Filed With SEC on January 18, 2022)

Asset Purchase Agreement between 9 Meters Biopharma, Inc. and Lobesity, LLC, dated July 19, 2021 (Filed With SEC on November 15, 2021)

Underwriting Agreement, dated March 30, 2021, by and between 9 Meters Biopharma, Inc., Citigroup Global Markets Inc., William Blair & Company, L.L.C., and Truist Securities, Inc (Filed With SEC on April 5, 2021)

Underwriting Agreement, dated December 11, 2020, by and between 9 Meters Biopharma, Inc., William Blair & Company, L.L.C., and Truist Securities, Inc., as representatives of the... (Filed With SEC on December 15, 2020)

Amendment to the 2012 Omnibus Incentive Plan, dated November 27, 2020 (Filed With SEC on November 27, 2020)

Amendment No. 1, dated October 2, 2020, to the Sales Agreement between 9 Meters Biopharma and Truist Securities, Inc (Filed With SEC on October 2, 2020)

Amended and Restated Exclusive License Agreement, dated February 10, 2020, between Cedars-Sinai Medical Center and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)

Side Letter, dated May 1, 20202, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)

Second Amended and Restated License Agreement, dated May 1, 2020, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)

Amended and Restated License Agreement, dated May 1, 2020, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)

Form of RDD Pharma Ltd. Notice of Option Grant (Filed With SEC on August 13, 2020)

Sales Agreement, dated as of July 22, 2020, between 9 Meters Biopharma, Inc. and SunTrust Robinson Humphrey, Inc (Filed With SEC on July 22, 2020)

9 Meters Biopharma, Inc. 2012 Omnibus Incentive Plan, as amended (Filed With SEC on June 30, 2020)

Agreement and Plan of Merger, dated April 30, 2020, among Innovate Biopharmaceuticals, Inc., Naia Merger Sub, Inc., Second Naia Merger Sub, LLC, and Naia Rare Diseases, Inc (Filed With SEC on May 4, 2020)

Form of Series A Convertible Preferred Stock Warrant (Filed With SEC on May 4, 2020)

Securities Purchase Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)

Registration Rights Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)

Form of Company Support Agreement by and among Innovate Biopharmaceuticals, Inc. and RDD Pharma Ltd (Filed With SEC on May 4, 2020)

Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Sandeep Laumas (Filed With SEC on May 4, 2020)

Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Jay Madan (Filed With SEC on May 4, 2020)

Employment Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and John Temperato (Filed With SEC on May 4, 2020)

Description of the Companys Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 20, 2020)

Executive Employment Agreement dated February 15, 2019, by and between the Company and Patrick H. Griffin, M.D (Filed With SEC on March 20, 2020)

Form of Amendment to Short-term Common Stock Purchase Warrant, dated February 6, 2020 (Filed With SEC on February 12, 2020)

Note issued to Atlas Sciences, LLC (Filed With SEC on January 10, 2020)

Note Purchase Agreement, dated January 10, 2020, by and between the Company and Atlas Sciences, LLC (Filed With SEC on January 10, 2020)

Form of Exchange Agreement (Filed With SEC on December 20, 2019)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of December 17, 2019, by and between Innovate Biopharmaceuticals, Inc., INNT Merger Sub 1 Ltd., RDD... (Filed With SEC on December 17, 2019)

Executive Employment Agreement, dated June 22, 2019, between the Company and Edward J. Sitar (Filed With SEC on June 27, 2019)

Form of Warrant (Filed With SEC on May 1, 2019)

Form of Placement Agent Warrant (Filed With SEC on May 1, 2019)

Form of Securities Purchase Agreement, dated April 29, 2019, by and among the Company and the purchasers party thereto (Filed With SEC on May 1, 2019)

Engagement Letter, dated April 26, 2019, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on May 1, 2019)

Amendment, dated April 25, 2019, to Securities Purchase Agreement, dated as of March 17, 2019, by and between the Company and the Purchasers party thereto (Filed With SEC on April 26, 2019)

First Amendment, dated February 19, 2019, to Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Sandeep Laumas (Filed With SEC on March 18, 2019)

Separation Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)

Consulting Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)

Separation Agreement, dated November 16, 2018, by and between the Company and June Almenoff (Filed With SEC on March 18, 2019)

Form of Long-Term Warrant (included in Exhibit 10.1) (Filed With SEC on March 18, 2019)

Note issued to Atlas Sciences, LLC (Filed With SEC on March 13, 2019)

Note Purchase Agreement, dated March 8, 2019, by and between the Company and Atlas Sciences, LLC (Filed With SEC on March 13, 2019)

Option to Purchase Senior Convertible Note, by and between the Company and Gustavia Capital Partners LLC and/or its affiliates dated as of January 7, 2019 (Filed With SEC on January 11, 2019)

2012 Omnibus Incentive Plan, as amended (Filed With SEC on December 10, 2018)

Master Services Agreement by and between the Company and Amarex Clinical Research, LLC, dated as of August 20, 2018 (Filed With SEC on November 13, 2018)

Non-Employee Director Compensation Policy dated as of September 21, 2018 (Filed With SEC on November 13, 2018)

Common Stock Sales Agreement by and among the Company and H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc. dated as of October 26, 2018 (Filed With SEC on October 29, 2018)

Amendment and Exchange Agreement by and between the Company and Gustavia Capital Partners LLC, dated as of October 4, 2018 (Filed With SEC on October 5, 2018)

Senior Convertible Note with Gustavia Capital Partners LLC (Filed With SEC on October 5, 2018)

Form of Share Certificate (Filed With SEC on March 14, 2018)

Sublicense Agreement, dated February 19, 2016, between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Alba Therapeutics Corporation (Filed With SEC on March 14, 2018)

License Agreement, dated February 26, 2016, between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Alba Therapeutics Corporation (Filed With SEC on March 14, 2018)

Asset Purchase Agreement, dated December 23, 2014, between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Repligen Corporation (Filed With SEC on March 14, 2018)

Apaza License Agreement, dated April 19, 2013, between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Seachaid Pharmaceuticals, Inc., as amended (Filed With SEC on March 14, 2018)

Innovate Biopharmaceuticals Inc. 2015 Stock Incentive Plan, as amended (Filed With SEC on March 14, 2018)

Form of Incentive Stock Option Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)

Form of Nonstatutory Stock Option Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)

Form of Restricted Stock Purchase Agreement under the 2015 Stock Incentive Plan (Filed With SEC on March 14, 2018)

Separation Agreement and Release of Claims, dated January 26, 2018, by and between the Company and David Olert (Filed With SEC on March 14, 2018)

Consulting Agreement, dated February 17, 2018, by and between the Company and David Olert (Filed With SEC on March 14, 2018)

Executive Employment Agreement, dated November 2, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Christopher Prior, as amended (Filed With SEC on March 14, 2018)

Executive Employment Agreement, dated October 28, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Sandeep Laumas, as amended (Filed With SEC on March 14, 2018)

Executive Employment Agreement, dated October 28, 2015, by and between Innovate Biopharmaceuticals Inc. (now IB Pharmaceuticals Inc.) and Jay Madan, as amended (Filed With SEC on March 14, 2018)

Executive Employment Agreement, dated March 9, 2018, by and between the Company and June Almenoff (Filed With SEC on March 14, 2018)

Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2018)

Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Sandeep Laumas (Filed With SEC on March 14, 2018)

Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Christopher Prior (Filed With SEC on March 14, 2018)

Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Jay Madan (Filed With SEC on March 14, 2018)

Form of Warrant (Filed With SEC on February 2, 2018)

Senior Note dated January 29, 2018 (Filed With SEC on February 2, 2018)

Amendment to Agreement and Plan of Merger and Reorganization by and among the Company, Merger Sub and Innovate date January 3, 2018 (Filed With SEC on January 5, 2018)

AGREEMENT AND PLAN OF MERGER ANDREORGANIZATION (Filed With SEC on July 6, 2017)

SUPPORT AGREEMENT (Filed With SEC on July 6, 2017)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 31, 2017)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 13, 2017)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 28, 2016)

SPECIMEN WARRANT CERTIFICATE (Filed With SEC on June 24, 2016)

WARRANT AGREEMENT (Filed With SEC on June 24, 2016)

Contract Manufacturer AGREEMENT SDJ Technologies, Inc. / Monster Digital (Filed With SEC on June 24, 2016)

UNDERWRITING AGREEMENT between MONSTER DIGITAL, INC. and AXIOM CAPITAL MANAGEMENT, INC. as Representative of the Several Underwriters (Filed With SEC on June 9, 2016)

UNIT PURCHASE OPTION FOR THE PURCHASE OF [•] UNITS OF SECURITIES OF MONSTER DIGITAL, INC. (Filed With SEC on June 9, 2016)

MONSTER DIGITAL,INC. WARRANT TO PURCHASECOMMON STOCK (Filed With SEC on June 7, 2016)

WARRANT AGREEMENT (Filed With SEC on June 7, 2016)

AMENDMENT NO. 4 TO TRADEMARK. LICENSE AGREEMENT (Filed With SEC on June 7, 2016)

SHARE CANCELLATION AGREEMENT (Filed With SEC on June 7, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)

AMENDMENT NO. 4 TO TRADEMARK. LICENSE AGREEMENT (Filed With SEC on June 7, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 7, 2016)

CONSULTING AGREEMENT (Filed With SEC on June 7, 2016)

MONSTER DIGITAL,INC. INCORPORATEDUNDER THE LAWS OF THE STATE OF DELAWARE (Filed With SEC on April 20, 2016)

SPECIMEN UNIT CERTIFICATE (Filed With SEC on April 20, 2016)

SPECIMEN UNIT WARRANT CERTIFICATE (Filed With SEC on April 20, 2016)

UNIT WARRANT AGREEMENT (Filed With SEC on January 11, 2016)

MONSTER DIGITAL,INC. WARRANT TO PURCHASECOMMON STOCK (Filed With SEC on January 11, 2016)

TRADEMARKLICENSE AGREEMENT (Filed With SEC on December 11, 2015)

FACTORING AGREEMENT (Filed With SEC on December 11, 2015)

TANDON DIGITAL, INC. 2012 OMNIBUS INCENTIVE PLAN Effective April 30, 2012 (Filed With SEC on November 10, 2015)

NOTICE OF GRANT OF[INCENTIVE/NON-QUALIFIED] STOCK OPTION AWARD TANDON DIGITTAL, INC. 2012 OMNIBUS INCENTIVEPLAN (Filed With SEC on November 10, 2015)

NOTICE OF GRANT OF RESTRICTED STOCK AWARD TANDON DIGITAL, INC. 2012 OMNIBUS INCENTIVE PLAN (Filed With SEC on November 10, 2015)

NOTICE OF GRANT OF RESTRICTED STOCK UNITAWARD TANDON DIGITAL, INC. 2012 OMNIBUS INCENTIVE PLAN (Filed With SEC on November 10, 2015)

AMENDMENT NO. 4 TO TRADEMARK.LICENSE AGREEMENT (Filed With SEC on November 10, 2015)

AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANTLEASE - NET (Filed With SEC on November 10, 2015)

PURCHASE ORDER PURCHASE AGREEMENT (Filed With SEC on November 10, 2015)

TANDON DIGITAL,INC. ADVISORY BOARD MEMBER AGREEMENT (Filed With SEC on November 10, 2015)

TANDONDIGITAL, INC. WARRANTTO PURCHASE COMMON STOCK (Filed With SEC on November 10, 2015)

CONSULTING AGREEMENT (Filed With SEC on November 10, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2015)

Category

Industry

Companies

Contracts

INNOVATE BIOPHARMACEUTICALS, INC. Contracts & Agreements